Progress on clinical application of bevacizumab for the treatment of refractory cervical cancer / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
;
(6): 395-402, 2016.
Artículo
en Chino
| WPRIM
| ID: wpr-239573
ABSTRACT
Bevacizumab is increasingly used in recurrent, persistent or metastatic cervical cancer. The early retrospective case reports found that bevacizumab combined with 5-FU (including capecitabine) or paclitaxel was well tolerated and displayed encouraging anti-tumor activity in recurrent or persistent cervical cancer. Phase Ⅱ clinical trials showed that bevacizumab was well tolerated and active in the second- and third-line treatment of patients with recurrent cervical cancer. Large scale phase Ⅱ and phase Ⅲ clinical trials demonstrated that bevacizumab-containing chemotherapy was effective in the first- and second-line treatment of patients with persistent cervical cancer, prolonged survival time and improved remission rate. The article also reviews the research progress on predictive factors of bevacizumab efficacy, showing the use of imaging and biomarkers in predicting the efficacy of bevacizumab treatment. In addition, this article analyzes the cost-effectiveness of bevacizumab, finding that bevacizumab combined with chemotherapy meets the standard of cost-effectiveness.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Inducción de Remisión
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Neoplasias del Cuello Uterino
/
Tasa de Supervivencia
/
Estudios Retrospectivos
/
Mortalidad
/
Resultado del Tratamiento
/
Costos de la Atención en Salud
/
Análisis Costo-Beneficio
/
Paclitaxel
Tipo de estudio:
Evaluación Económica en Salud
/
Estudio observacional
/
Estudio pronóstico
Límite:
Femenino
/
Humanos
Idioma:
Chino
Revista:
Journal of Zhejiang University. Medical sciences
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS